Peter Ordentlich net worth and biography

Peter Ordentlich Biography and Net Worth

Peter Ordentlich, Ph.D. co-founded the Company in October 2005 and has served as our Chief Scientific Officer since September 2016. Dr. Ordentlich previously served as our Chief Technical Officer from November 2013 to August 2016, our Vice President, Translational Medicine from January 2012 to October 2013, our Executive Director, Translational Science from January 2011 to December 2011, and our Director, Scientific Affairs and Strategic Alliances from January 2008 to December 2010. Prior to founding the company, Dr. Ordentlich was a scientist at the Salk Institute for Biological Studies, a biological research non-profit organization. He also spent five years as a research scientist at X-Ceptor Therapeutics, Inc., a drug discovery company, which was acquired by Exelixis, Inc. Dr. Ordentlich received a B.A. in Biochemistry and a Ph.D. in Immunology from the University of Pennsylvania.

What is Peter Ordentlich's net worth?: The estimated net worth of Peter Ordentlich is at least $4,226.75 as of December 1st, 2022. Dr. Ordentlich owns 265 shares of Syndax Pharmaceuticals stock worth more than $4,227 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Ordentlich may own. Learn More about Peter Ordentlich's net worth.
How old is Peter Ordentlich?: Dr. Ordentlich is currently 55 years old. There are 4 older executives and no younger executives at Syndax Pharmaceuticals. The oldest executive at Syndax Pharmaceuticals is Dr. Ronald M. Evans Ph.D., Co-Founder, Advisor and Chair of Scientific Advisory Board, who is 75 years old. Learn More on Peter Ordentlich's age.
How do I contact Peter Ordentlich?: The corporate mailing address for Dr. Ordentlich and other Syndax Pharmaceuticals executives is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. Syndax Pharmaceuticals can also be reached via phone at (781) 419-1400 and via email at [email protected]. Learn More on Peter Ordentlich's contact information.
Has Peter Ordentlich been buying or selling shares of Syndax Pharmaceuticals?: Peter Ordentlich has not been actively trading shares of Syndax Pharmaceuticals over the course of the past ninety days. Most recently, Peter Ordentlich sold 25,000 shares of the business's stock in a transaction on Wednesday, February 15th. The shares were sold at an average price of $25.84, for a transaction totalling $646,000.00. Learn More on Peter Ordentlich's trading history.
Who are Syndax Pharmaceuticals' active insiders?: Syndax Pharmaceuticals' insider roster includes Fabrice Egros (Director), Pierre Legault (Director), Michael Metzger (COO), Michael Meyers (SVP), Briggs Morrison (CEO), Alexander Nolte (CAO), Peter Ordentlich (Insider), and Dennis Podlesak (Director). Learn More on Syndax Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Syndax Pharmaceuticals?: In the last year, Syndax Pharmaceuticals insiders bought shares 1 times. They purchased a total of 1,250 shares worth more than $25,037.50. The most recent insider tranaction occured on June, 14th when CFO Keith A Goldan bought 1,250 shares worth more than $25,037.50. Insiders at Syndax Pharmaceuticals own 4.1% of the company. Learn More about insider trades at Syndax Pharmaceuticals.
Information on this page was last updated on 6/14/2024.

Peter Ordentlich Insider Trading History at Syndax Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/15/2023	Sell	25,000	$25.84	$646,000.00
12/1/2022	Sell	7,800	$25.01	$195,078.00	265
8/24/2022	Sell	25,000	$25.04	$626,000.00	265
2/1/2022	Sell	1,412	$16.65	$23,509.80
11/23/2020	Sell	29,972	$23.16	$694,151.52	24,288
4/3/2018	Sell	7,500	$15.00	$112,500.00
5/17/2017	Sell	5,000	$15.00	$75,000.00	5,000

Peter Ordentlich Buying and Selling Activity at Syndax Pharmaceuticals

Syndax Pharmaceuticals Company Overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $15.95

$15.34

$16.19

50 Day Range

MA: $18.76

$15.77

$21.81

2 Week Range

Now: $15.95

$14.97

$25.34

Volume

1,261,777 shs

Average Volume

2,036,181 shs

Market Capitalization

$1.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Trump’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

Peter Ordentlich Biography and Net Worth

What is Peter Ordentlich's net worth?

How old is Peter Ordentlich?

How do I contact Peter Ordentlich?

Has Peter Ordentlich been buying or selling shares of Syndax Pharmaceuticals?

Who are Syndax Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Syndax Pharmaceuticals?